Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors

ABSTRACT

The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds which are useful for inhibiting protein tyrosine phosphatases, particularly PTP1B, and are useful for lowering blood glucose concentrations in mammals.

PRIORITY TO PROVISIONAL APPLICATION(S) UNDER 35 U.S.C. §119(e)

[0001] This application claims priority under 35 U.S.C. §119(e) of provisional application(s) Ser. No. 60/470,803, filed May 15, 2003 and Ser. No. 60/563,584, filed Apr. 19, 2004.

FIELD OF THE INVENTION

[0002] The invention relates to diaminopyrroloquinazolines compounds useful for inhibiting protein tyrosine phosphatases, particularly PTP1B, and are useful for lowering blood glucose concentrations in mammals.

BACKGROUND OF THE INVENTION

[0003] Protein tyrosine phosphatases (PTPases) are key enzymes in processes that regulate cell growth and differentiation. The inhibition of these enzymes can play a role in the modulation of multiple signaling pathways in which tyrosine phosphorylation dephosphorylation plays a role. PTP1B is a particular protein tyrosine phosphatases that is often used as a prototypical member of that class of enzymes.

[0004] PTPase inhibitors are recognized as potential therapeutic agents for the treatment of diabetes. See, e.g. Moeller et al., 3(5):527-40, Current Opinion in Drug Discovery and Development, 2000; or Zhang, Zhong-Yin, 5:416-23, Current Opinion in Chemical Biology, 2001. The utility of PTPase inhibitors as therapeutic agents has been a topic of discussion in several review articles including, for example, Expert Opin Investig Drugs, 12(2):223-33, Feb. 2003.

SUMMARY OF THE INVENTION

[0005] It has been discovered that compounds of the formula:

[0006] wherein

[0007] R₁ is selected from hydrogen and lower alkyl;

[0008] R₂ is selected from the group consisting of hydrogen, lower alkyl,

[0009] R₃ and R₄ are independently selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkoxy, hydroxy lower alkyl, perfluoroloweralklyl, nitro, halo, lower alkanoyl, —N R₅R₆, R₇S—,

[0010] phenyl, hydroxy, perfluoroloweralkoxy, and phenoxy, or

[0011] R₃ and R₄ when present on adjacent carbon atoms on the phenyl ring can be taken together with their adjacent carbon atoms to form a lower alkylenedioxy bridge or an aromatic ring system fused to the phenyl ring, said aromatic ring system containing one or two aromatic rings with one of said rings being either an aromatic or heteroaromatic ring;

[0012] R₅ and R₆ are independently selected from hydrogen and lower alkyl;

[0013] R₁₂ is selected from the group consisting of hydrogen, benzyl, phenyl and lower alkyl;

[0014] R₇ is lower alkyl;

[0015] R₁₃ is selected from the group consisting of hydrogen, lower alkyl, benzyl and phenyl;

[0016] R₁₀, R₁₁ and R₁₂ are independently selected from hydrogen and lower alkyl; and

[0017] m, n, o and v are independent integers selected from 0 to 4,

[0018] or pharmaceutically acceptable salts thereof,

[0019] inhibit protein tyrosine phosphatases, particularly PTP1B and are therefore useful for lowering blood glucose concentrations in mammals.

[0020] In another embodiment, it has also been discovered that compounds of the formula:

[0021] wherein

[0022] {circle over (P)} is a 5 or 6 membered heteroaromatic ring containing from 1 to 2 hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen;

[0023] R1 is selected from hydrogen and lower alkyl;

[0024] R₂ is selected from the group consisting of hydrogen, lower alkyl,

[0025] R₃ and R₄ are independently selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkoxy, hydroxy lower alkyl, perfluoroloweralklyl, nitro, halo, lower alkanoyl, —N R₅R₆R₇S—,

[0026] phenyl, hydroxy, perfluoroloweralkoxy, and phenoxy, or

[0027] R₃ and R₄ when present on adjacent carbon atoms on the heteroaromatic ring can be taken together with their adjacent carbon atoms to form a lower alkylenedioxy bridge or an aromatic ring system fused to the phenyl ring, said aromatic ring system containing one or two aromatic rings with one of said rings being either an aromatic or heteroaromatic ring;

[0028] R₅ and R₆ are independently selected from hydrogen and lower alkyl;

[0029] R₂ is selected from the group consisting of hydrogen, benzyl, phenyl and lower alkyl;

[0030] R₇ is lower alkyl;

[0031] R₁₃ is selected from the group consisting of hydrogen, lower alkyl, benzyl and phenyl;

[0032] R₁₀, R₁₁ and R₁₂ are independently selected from hydrogen and lower alkyl; and

[0033] m, n, o and v are independent integers selected from 0 to 4,

[0034] or pharmaceutically acceptable salts thereof,

[0035] inhibit protein tyrosine phosphatases, particularly PTP1B and are therefore useful for lowering blood glucose concentrations in mammals.

DETAILED DESCRIPTION OF THE INVENTION

[0036] The present invention comprises compounds of the formula:

[0037] wherein

[0038] R₁ is selected from hydrogen and lower alkyl;

[0039] R₂ is selected from the group consisting of hydrogen, lower alkyl,

[0040] R₃ and R₄ are independently selected from hydrogen, lower alkyl, lower alkenyl, lower alkoxy, hydroxy lower alkyl, perfluoroloweralklyl, nitro, halo, lower alkanoyl, —N R₅R₆, R₇S—,

[0041] phenyl, hydroxy, perfluoroloweralkoxy, and phenoxy, or

[0042] R₃ and R₄ when present on adjacent carbon atoms on the phenyl ring can be taken together with their adjacent carbon atoms to form a lower alkylenedioxy bridge or an aromatic ring system fused to the phenyl ring, said aromatic ring system containing one or two aromatic rings with one of said rings being either an aromatic or heteroaromatic ring;

[0043] R₅ and R₆ are independently selected from hydrogen and lower alkyl;

[0044] R₁₂ is selected from the group consisting of hydrogen, benzyl, phenyl and lower alkyl;

[0045] R₇ is lower alkyl;

[0046] R₁₃ is selected from the group consisting of hydrogen, lower alkyl, benzyl and phenyl;

[0047] R₁₀, R₁₁, and R₁₂ are independently selected from hydrogen and lower alkyl; and

[0048] m, n, o and v are independent integers selected from 0 to 4,

[0049] or pharmaceutically acceptable salts thereof,

[0050] inhibit protein tyrosine phosphatases, particularly PTP1B and are therefore useful for lowering blood glucose concentrations in mammals.

[0051] Another embodiment of the compounds of this invention comprises compounds of the formula:

[0052] wherein

[0053] {circle over (P)} is a 5 or 6 membered heteroaromatic ring containing from 1 to 2 hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen;

[0054] R1 is selected from hydrogen and lower alkyl;

[0055] R₂ is selected from the group consisting of hydrogen, lower alkyl,

[0056] R₃ and R₄ are independently selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkoxy, hydroxy lower alkyl, perfluoroloweralklyl, nitro, halo, lower alkanoyl, —N R₅R₆R₇S—,

[0057] phenyl, hydroxy, perfluoroloweralkoxy, and phenoxy, or

[0058] R₃ and R₄ when present on adjacent carbon atoms on the heteroaromatic ring can be taken together with their adjacent carbon atoms to form a lower alkylenedioxy bridge or an aromatic ring system fused to the phenyl ring, said aromatic ring system containing one or two aromatic rings with one of said rings being either an aromatic or heteroaromatic ring;

[0059] R₅ and R₆ are independently selected from hydrogen and lower alkyl;

[0060] R₂ is selected from the group consisting of hydrogen, benzyl, phenyl and lower alkyl;

[0061] R₇ is lower alkyl;

[0062] R₁₃ is selected from the group consisting of hydrogen, lower alkyl, benzyl and phenyl;

[0063] R₁₀, R₁₁, and R₁₂ are independently selected from hydrogen and lower alkyl; and

[0064] m, n, o and v are independent integers selected from 0 to 4,

[0065] or pharmaceutically acceptable salts thereof,

[0066] inhibit protein tyrosine phosphatases, particularly PTP1B and are therefore useful for lowering blood glucose concentrations in mammals.

[0067] As used in the specification, the term “lower alkyl”, alone or in combination, means a straight-chain or branched-chain alkyl group containing from one to six carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl and the like.

[0068] The term “cycloalkyl” means an unsubstituted or substituted 3- to 7-membered saturated carbocyclic ring.

[0069] The term lower “alkoxy” means a straight-chain or branched-chain alkoxy group containing from one to six carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy and the like.

[0070] The term “heteroaromatic” means a mono-cyclic heteroaromatic ring or a fused ring system containing one or more hetero atoms in the ring system such as nitrogen atom, oxygen atom and sulphur atom within the ring or ring system. Examples of “heteroaryl group” are pyridyl group, thienyl group and furyl.

[0071] The term “aryl” means a mono- or bicyclic aromatic group, such as phenyl or naphthyl, which is unsubstituted or substituted by conventional substituent groups.

[0072] The term “lower alkylenedioxy” denotes a divalent saturated hydrocarbon moiety containing from one to six carbon atoms having terminal oxygens which are placed at the end of the lower alkylene chain and connect to the rest of the molecule. The preferred lower alkylenedioxy moieties are 1,2-ethylene dioxy, methylene dioxy, 1,3-propylene dioxy. Generally, the preferred lower alkylene dioxy moieties are formed in a straight chain.

[0073] The term “pharmaceutically acceptable salts” refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formulas I, II, III and IV and are formed from suitable non-toxic organic or inorganic acids, or organic or inorganic bases. Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Sample base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethylammonium hydroxide. The chemical modification of a pharmaceutical compound (i.e., drug) into a salt is a technique well known to pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. See, e.g., H. Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 196 and 1456-1457.

[0074] The preferred compounds of the Compounds of Formula I-A and I-B above are those compounds where R₁ is hydrogen. Particularly preferred among those classes of compounds where R₁ is hydrogen are those compounds where R₂ is hydrogen or lower alkyl.

[0075] There are many different embodiments of the compounds of formula I-A. The main embodiments of the compounds of formula I-A are first, those compounds where R₃ and R₄ are present on the phenyl ring on the compound of formula I-A on adjacent carbon atoms and taken together form a lower alkylene dioxy bridge. The second major embodiment are those compounds of formula I-A where R₃ and R₄ are present on adjacent carbon atoms on the phenyl ring and are taken together with their adjacent carbon atoms to form an aromatic ring system fused to the phenyl ring. The third major embodiment are those compounds where R₃ and R₄ are individual, connected to the phenyl ring.

[0076] In the first embodiment where R₃ and R₄ form a lower alkylenedioxy bridge, these bridges preferably contain from one to three carbon atoms. In a preferred class of this embodiment, R₂is hydrogen or lower alkyl and R₁ is hydrogen or lower alkyl, preferably hydrogen.

[0077] The second major embodiment of the compounds of formula I-A are those compounds where R₃ and R₄ are substituted on adjacent carbon atoms and taken together with their attached carbon atoms form a fused aromatic ring system containing from 1 to 3 fused rings fused to the phenyl ring on the compound of formula I-A. One class of compounds in this embodiment are those compounds where the fused aromatic ring system, fused to the phenyl ring on the compound of formula I-A, can contain one hetero aromatic ring and/or one hetero aromatic and/or one aromatic ring. In the embodiment where R₃ and R₄ form a fused aromatic ring system, R₁ is preferably hydrogen and R₂ is preferably hydrogen or lower alkyl. In this second major embodiment of the compounds of formula I-A, another class of compounds are those compounds where R₃ and R₄ when taken together with their attached carbon atoms form a single fused heteroaromatic ring or an aromatic ring such as phenyl. In this embodiment R₁ and R₂ are preferably hydrogen or lower alkyl. In this second major embodiment of the compounds of formula I-A, another class of compounds are those compounds where R₃ and R₄ when taken together with their attached carbon atoms form a two membered fused ring system which is fused to the phenyl group on the compound of formula I. These two membered ring systems can be both aromatic rings or one hetero aromatic ring and one aromatic ring.

[0078] In the third major embodiment, R₃ and R₄ are independent groups separately attached to the phenyl moiety in the compound of formula I-A. One of the compounds within this embodiment include compounds where R₁ and R₂ are independently hydrogen or lower alkyl and R₃ and R₄ are independently hydrogen, lower alkyl or lower alkenyl. In this preferred group of compounds, lower alkenyl denotes a monovalent aliphatic hydrocarbon substituent containing from two to six carbon atoms and having an unsubstituted double bond within its structure. The preferred group of compounds where R₄is lower alkenyl are compounds where R₃is hydrogen and R₁ and R₂ are independently hydrogen or lower alkyl.

[0079] Another class of compounds within the compounds of formula I-A where R₃ and R₄ are independent substituents are those compounds where R₃ and R₄ are individually hydrogen, halogen, trifluoroloweralkyl, preferably trifluoromethyl, and trifluoroloweralkoxy, preferably trifluoromethoxy, with one of R₃ and R₄ being other than hydrogen. Within this class of compounds are those compounds where R₁ and R₂ are either hydrogen or lower alkyl.

[0080] Another class of compounds within the embodiment of R₃and R₄ being individual separate substituents are those compounds where R₃ is hydrogen or halogen and R₄ is halogen, nitro, lower alkoxy, phenoxy, hydroxy or hydroxyalkyl. Among this class of compounds, compounds where R₁ and R₂ are hydrogen or lower alkyl are preferred. In another class of compounds within this embodiment, where R₃ is halogen or hydrogen, another class of compounds are those where R₄ is:

[0081] v is an integer from 0 to 4;

[0082] R₁₂ is hydrogen or lower alkyl. In this embodiment, R₄ can be either an aldehyde, where

[0083] R₁₂ is H or a ketone where R₁₂ is lower alkyl. Also in this regard, R₃ and R₄ can form one or two lower carboxylic acid groups.

[0084] In accordance with another embodiment of the compound of formula I-A where R₃ and R₄ are independent substituents, there are those compounds where R₁ and R₂ are independently hydrogen or lower alkyl;R₃ and R₄ are hydrogen, R₇S—, R₅R₆ N—, or

[0085] R₅ and R₆ are independently hydrogen or lower alkyl;

[0086] R₇ is lower alkyl; and

[0087] one of R₃ and R₄ is other than hydrogen.

[0088] Furthermore, in accordance with the embodiment of this invention where R₃ and R₄ in the compound of formula I- A are independent substituents are those class of compounds where R₂ is

[0089] R₁₃ is hydrogen, phenyl, benzyl or lower alkyl; and

[0090] m and n is an integer from 0 to 4. In this case R₁ is generally hydrogen or lower alkyl, preferably hydrogen. In addition, R₃ and R₄ can be halogen or trifluoroalkyl, preferably trifluoromethyl with one of R₃ and R₄ being halogen or hydrogen.

[0091] In another class of compounds where R₃ and R₄ are separate independent substituents are those compounds where R₂ is

[0092] R₁₀ and R₁₁ are independently hydrogen or lower alkyl. In this group of compounds, R1 is hydrogen or lower alkyl, preferably hydrogen. Also, with respect to this class of compounds, R₃ and R₄ are preferably hydrogen or lower alkoxy.

[0093] The compound of formula I-B contains various different embodiments in the same manner as the compound of formula I-A. The first major embodiment are those compounds where R₃ and R₄ taken together form a lower alkylene dioxy bridge. The second are those compounds where R₃ and R₄ taken together with their adjacent carbon atoms to form an aromatic ring system which contains one or two aromatic or heteroaromatic rings fused to the heteroaromatic ring {circle over (P)} in the compound of formula I-B. On the other hand, in accordance with a third embodiment of this invention, the compound of R₃ and R₄ on the compound of formula I-B can be independent, individual substituents. The embodiments formed in this manner are the same as set forth with regard to compounds I-A.

[0094] In addition, since the compound of formula I-B contains within its structure a heteroaromatic ring, this heteroaromatic ring can contain sulfur, oxygen or nitrogen as the only hetero atom. On the other hand, this structure can contain two hetero atoms with each being the same or each being a different hetero atom such as oxygen or nitrogen. One such embodiment of those compounds, where the hetero aromatic ring contains sulfur as the only hetero atom. In this embodiment, the class of compounds where R₃ and R₄ are independently halogen or lower alkyl are preferred. In addition, those class of compounds where R₃ and R₄ are independently hydrogen, halogen or lower alkyl and R₁ and R₂ are hydrogen and lower alkyl are especially preferred.

[0095] In addition, with respect to those compounds of formula I-B where the hetero aromatic ring in this compound contains the sulfur atom as the only hetero atom in its ring, the class of compounds where R₃ and R₄ is hydrogen, or

[0096] R₁₂ is hydrogen or lower alkyl; and

[0097] R₃ and R₄ is other than hydrogen are preferred. In this embodiment, those compounds where R₁ and R₂ are hydrogen and lower alkyl are especially preferred.

[0098] As indicated hereinabove, R₃ and R₄ which are present when attached on adjacent carbon atoms on the hetero aromatic ring can be taken together with their attached carbon atoms to form a fused ring system. This ring system can be either a hetero aromatic ring or an aromatic ring. The preferred fused aromatic ring is a phenyl ring.

[0099] This invention is also directed to a pharmaceutical composition comprising one or more compounds of formulas I-A and I-B.

[0100] Moreover, this invention is directed to a method of treating a disease based on high blood glucose concentration comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one compound of the formulas I-A and I-B.

[0101] The compounds of the invention can exist as stereoisomers and diastereomers, all of which are encompassed within the scope of the present invention.

[0102] The compounds of the invention inhibit PTP1B in vitro and have been shown to lower blood glucose levels in vivo. Thus, the compounds of the present invention would be useful for the treatment of diabetes.

[0103] The compounds of the invention can be administered orally, rectally, or parentally, e.g., intravenously, intramuscularly, subcutaneously, intrathecally or transdermally; or sublingually, or as opthalmalogical preparations. Capsules, tablets, suspensions or solutions for oral administration, suppositories, injection solutions, eye drops, salves or spray solutions are examples of administration forms.

[0104] Intravenous, intramuscular, oral or inhalation administration are preferred forms of use. The dosages in which the compounds of the invention are administered in effective amount depend on the nature of the specific active ingredient, the age and requirements of the patient and the mode of administration. Dosages may be determined by any conventional means, e.g., by dose-limiting clinical trials. In general, dosages of about 0.1 to 100 mg/kg body weight per day are preferred, with dosages of 1-25 mg/kg per day being particularly preferred.

[0105] The invention further comprises pharmaceutical compositions that contain a pharmaceutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. Such compositions may be formulated by any conventional means. Tablets or granulates can contain a series of binders, fillers, carriers or diluents. Liquid compositions can be, for example, in the form of a sterile water-miscible solution. Capsules can contain a filler or thickener in addition to the active ingredient. Furthermore, flavor-improving additives as well as substances usually used as preserving, stabilizing, moisture-retaining and emulsifying agents as well as salts for varying the osmotic pressure, buffers and other additives can also be present.

[0106] The previously mentioned carrier materials and diluents can comprise any conventional pharmaceutically acceptable organic or inorganic substances, e.g., water, gelatine, lactose, starch, magnesium stearate, talc, gum arabic, polyalkylene glycols and

[0107] Oral unit dosage forms, such as tablets and capsules, preferably contain from 25 mg to 1000 mg of a compound of the invention. The compounds of the invention may be prepared by any conventional means.

[0108] In accordance with this invention, the compounds herein as well as their pharmaceutically acceptable salts are useful in the control or prevention of illnesses associated with high blood glucose concentration. A preferred indication associated with the present invention is that associated with diabetes.

[0109] The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration, the dosage for adults may vary from about 0.01 mg to about 1000 mg per day of a compound of formula I-A and I-B or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses, and in addition, the upper limit can also be exceeded when this is found to be indicated.

[0110] A particular method is described in the following Schemes 1 and 2. The examples following each of the schemes provide a detailed description of the schematic methods. In the following reaction schemes

[0111] designates a phenyl ring or {circle over (P)} which is a heteroaromatic ring. In the following schemes, R₈ and R₉ are the same as R₃ and R₄.

[0112] Compound II: A mixture of silver sulfate (100 g, 0.32 mol) and iodine (82 g, 0.32 mol) in N,N-dimethylformamide (700 mL) and ethanol (1400 mL) was treated with 5-nitro-2,3-dihydro-1H-indole I (48 g, 0.29 mol). The resulting mixture was stirred at 25° C. for 1.5 h, filtered and the filter pad washed with ethyl acetate. The filtrate was concentrated in vacuo to a volume of approximately 500 mL. This solution was treated with a 1.0N aqueous sodium thiosulfate solution (100 mL) and a saturated aqueous sodium chloride solution (400 mL). The resulting precipitate was collected by filtration, washed with water and petroleum ether, and dried in vacuo to afford 7-iodo-5-nitro-2,3-dihydro-1H-indole II (83.9 g, 98.9%) as a white solid: ¹H NMR (DMSO-d₆, 300 MHz) δ 8.18 (d, J=2.20 Hz, 1H), 7.80 (d, J=1.46 Hz, 1H), 7.03 (broad s, 1H), 3.65 (t, J=8.97 Hz, 2H), 3.17 (t, J=8.60 Hz, 2H).

[0113] Compound III: A solution of 7-iodo-5-nitro-2,3-dihydro-1H-indole II (15 g, 51.7 mmol) in ethanol (1200 mL) and isopropanol (20 mL) at 25° C. was treated with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (13.6 g, 59.9 mmol). The resulting solution was warmed to 65° C. and air was bubbled through for 1 h. An additional 0.57 equivalents of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (6.8 g, 29.9 mmol) was added and the reaction was stirred at 65° C. for another 2 h before being concentrated in vacuo. Flash chromatography (Merck Silica gel 60, 230-400 mesh, 90/10 toluene/ethyl acetate) afforded 7-iodo-5-nitro-1H-indole III (13.07 g, 79%) as a yellow solid: ¹H NMR (DMSO-d_(6,) 300 MHz) δ 11.82 (broad s, 1H), 8.59 (d, J=1.83 Hz, 1H), 8.30 (d, J=1.83 Hz, 1H), 7.61 (t, J=2.93 Hz, 1H), 6.90 (dd, J₁=1.83 Hz, J₂=3.30 Hz, 1H).

[0114] Compound IV: A solution of 7-iodo-5-nitro-1H-indole III (20 g, 69.4 mmol) in methanol (650 mL) at 25° C. was treated with a solution of ammonium chloride (26.1 g, 485.8 mmol) in water (550 mL) and iron powder (13.6 g, 242.9 mmol). The mixture was heated to 100° C. under a nitrogen atmosphere for 5 h. The resulting mixture was filtered through a pad of celite and the celite pad washed with hot methanol. The filtrate was concentrated in vacuo and the residue was partitioned between methylene chloride and water and separated. The pH of the aqueous layer was adjusted to pH=10 with ammonium hydroxide and extracted with methylene chloride. The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to a volume of 250 mL. This solution was treated with a 4.0M aqueous hydrochloric acid solution in dioxane and stirred at 25° C. for 2 h. The precipitate was collected by filtration and washed with methylene chloride and petroleum ether to afford 7-iodo-1H-indol-5-ylamine hydrochloride IV (24.7 g, quant.) as a gray solid: ¹H NMR (DMSO-d6, 300 MHz) δ 11.34 (broad s, 1H), 9.93 (broad s, 2H), 7.56 (d, J=1.46 Hz, 1H), 7.48 (t, J=2.74 Hz, 1H), 7.44 (d, J=1.83 Hz, 1H), 6.68 (dd, J₁=1.83 Hz, J₂=2.93 Hz, 1H).

[0115] Compound V: A solution of 7-iodo-1H-indol-5-ylamine hydrochloride IV (24.6 g, 83.7 mmol) in N,N-dimethylformamide (400 mL) at 25° C. was treated with sodium dicyanamide (18.6 g, 209 mmol). The reaction mixture was warmed to 50° C. for 2 h, concentrated in vacuo, and the residue treated with water (500 mL). The resulting mixture was allowed to stand at 25° C. for 2.5 h during which time a yellow precipitate formed. The precipitate was collected by filtration and washed with water to afford N″-cyano-N-(7-iodo-1H-indol-5-yl)guanidine V (22.59 g, 83%) as a light yellow solid: ¹H NMR (DMSO-d₆, 300 MHz) δ 11.02 (broad s, 1H), 8.89 (broad s, 1H), 7.46 (d, J=1.83 Hz, 1H), 7.37 (d, J=1.83 Hz, 1H), 7.35 (t, J=2.56 Hz, 1H), 6.85 (broad S, 2H), 6.56 (dd, J₁=1.83 Hz, J₂=3.10 Hz, 1H).

[0116] Compound VI: A solution of N″-cyano—N-(7-iodo-1H-indol-5-yl)guanidine V (6.0 g, 18.7 mmol) in 2-methoxyethyl ether (50 mL) was heated to 175° C. for 32.5 h. The reaction mixture was cooled to 25° C., the resulting solids removed by filtration and washed with methanol. The filtrate was concentrated in vacuo to give a brown oil. The residue was dissolved in methanol and then absorbed onto Merck Silica gel 60, 230-400 mesh (25 g). Flash chromatography (Merck Silica gel 60, 230-400 mesh, 90/10/1 methylene chloride/methanol/ammonium hydroxide) afforded 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine VI (3.61 g, 59%) as a brown solid: ¹H NMR (DMSO-d₆, 300 MHz) δ 11.36 (broad s, 1H), 7.45 (broad s, 1H), 7.43 (t, J=2.93 Hz, 1H), 7.20 (s, 1H), 6.74 (broad s, 2H), 5.78 (broad s, 2H).

[0117] Compound VII: The coupling reaction can be carried out by a conventional aryl coupling method, e.g., Suzuki coupling method: (a) Suzuki et al., synth.commun. 1981, 11, 513, (b) Suzuki pure and Appl. Chem. 1985, 57, 1749-1758, (c) Suzuki et al., Chem. Rev. 1995, 95,2457-2483, (d) Shieh et al., J. Org. Chem. 1992,57,379-381, (e) Martin et al., Acta Chemica Scandinavica. 1993, 47, 513.

[0118] Typical conditions used to carry out the Suzuki coupling of 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine VI includes the use of either aryl or heteroaromatic boronic acid or esters (e.g., where Ar is defined as aryl) as coupling partner, in aqueous base such as sodium bicarbonate or potassium carbonate or barium hydroxide or triethylamine solution, a palladium catalyst (2-20 mole %) such as tetrakis(triphenylphosphine)-palladium (o) or [1,1′bis(diphenylphosphino)-ferrocene]dichloro-palladium(II), in a suitable solvent such as aqueous ethanol or THF or DMF or ethylene glycol for at temperatures ranging from 25° C. to 125° C. for 2-18 hr yields compound VII.

[0119] Alternatively, coupling reaction can be carried out by a conventional aryl or heteroaromatic coupling partner utilizing Stille coupling, e.g., Stille et al., Angew. Chem. Int. Ed. Engl., 1986,25,508.

[0120] Typical conditions used to carry out the Stille reaction include the use of an organostannane as the coupling partner, palladium catalyst (2-20 mole %) such as tetrakis(triphenylphosphine)-palladium (o) or [1,1′bis(diphenylphosphino)-ferrocene]dichloro-palladium(II), a salt such as potassium fluoride or lithium chloride, in a suitable anhydrous solvent such as THF or DMF or ethylene glycol for at temperatures ranging from 25° C. to 125° C. for 2-18 hr yields compound VII.

[0121] Compound VIII: A solution of 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine VI, 400 mg, 1.23 mmol) in tetrahydrofuran (20 mL) at 25° C. was treated with sodium hydroxide (98 mg, 2.46 mmol), methyl iodide (0.09 mL, 1.48 mmol), and tetrabutylammonium bromide (198 mg, 0.62 mmol), and the resulting mixture stirred at 25° C. for 18 h. The reaction mixture was treated with ethyl acetate, water, and a saturated aqueous sodium chloride solution, shaken and separated. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to afford 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (500 mg) as a yellow solid. The product was taken on into the next reaction without further purification 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine VIII.

[0122] Compound IX: The coupling reaction can be carried out by a conventional aryvl coupling method, e.g., Suzuki coupling method: (a) Suzuki et al., synth.commun. 1981, 11, 513, (b) Suzuki pure and Appl. Chem. 1985, 57, 1749-1758, (c) Suzuki et al., Chem. Rev. 1995, 95,2457-2483, (d) Shieh et al., J. Org. Chem. 1992,57,379-381, (e) Martin et al., Acta Chemica Scandinavica. 1993, 47,513.

[0123] Typical conditions used to carry out the Suzuki coupling of VIII includes the use of either aryl or heteroaromatic boronic acid or esters (e.g., where Ar is defined as aryl) as coupling partner, in aqueous base such as sodium bicarbonate or potassium carbonate or barium hydroxide or triethylamine solution, a palladium catalyst (2-20 mole %) such as tetrakis(triphenylphosphine)-palladium (o) or [1,1′-bis(diphenylphosphino)-ferrocene]dichloro-palladium(II), in a suitable solvent such as aqueous ethanol or THF or DMF or ethylene glycol for at temperatures ranging from 25° C. to 125° C. for 2-18 hr yields 6-Aryl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine X.

[0124] Alternatively, coupling reaction can be carried out by a conventional aryl or heteroaromatic coupling partner utilizing Stille coupling, e.g., Stille et al., Angew. Chem. Int. Ed. Engl., 1986, 25, 508.

[0125] Typical conditions used to carry out the Stille reaction include the use of an organostannane as the coupling partner, palladium catalyst (2-20 mole %) such as tetrakis(triphenylphosphine)-palladium (o) or [1,1′bis(diphenylphosphino)-ferrocene]dichloro-palladium(II), a salt such as potassium fluoride or lithium chloride, in a suitable anhydrous solvent such as THF or DMF or ethylene glycol for at temperatures ranging from 25° C. to 125° C. for 2-18 hr yields compound 6-Aryl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine IX.

[0126] Compound X: Typical condition used to carry out alkylation of 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine VI and phase transfer catalyst such as tetrabutylammonium bromide, with variety of halides (e.g. RaBr or RaI, where Ra is defined above) is carried out with suitable solvent such as tetrahydrofuran, DMF using suitable base such as sodium hydroxide at temperatures ranging from −78° C. to 25° C. to provide the 6-iodo-7-alkyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine XI.

[0127] 6-Aryl-7-alkyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine XI: The coupling reaction can be carried out by a conventional aryl coupling method, e.g., Suzuki coupling method: (a) Suzuki et al., synth.commun. 1981, 11, 513, (b) Suzuki, Pure and Appl. Chem. 1985, 57, 1749-1758, (c) Suzuki et al., Chem. Rev. 1995, 95, 2457-2483, (d) Shieh et al., J. Org. Chem. 1992, 57, 379-381, (e) Martin et al., Acta Chemica Scandinavica. 1993, 47, 513.

[0128] Typical conditions used to carry out the Suzuki coupling of 6-iodo-7-alkyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine X includes the use of either aryl or heteroaromatic boronic acid or esters (e.g. where Ar is defined as aryl) as coupling partner, in aqueous base such as sodium bicarbonate or potassium carbonate or barium hydroxide or triethylamine solution, a palladium catalyst (2-20 mole %) such as tetrakis(triphenylphosphine)-palladium (o) or [1,1′bis(diphenylphosphino)-ferrocene]dichloro-palladium(II), in a suitable solvent such as aqueous ethanol or THF or DMF or ethylene glycol for at temperatures ranging from 25° C. to 125° C. for 2-18 hr yields compound X.

[0129] Alternatively, coupling reaction can be carried out by a conventional aryl or heteroaromatic coupling partner utilizing Stille coupling. e.g., Stille et al., Angew. Chem. Int. Ed. Engl., 1986, 25, 508.

[0130] Typical conditions used to carry out the Stille reaction include the use of an organostannane as the coupling partner, palladium catalyst (2-20 mole%) such as tetrakis(triphenylphosphine)-palladium (o) or [1,1′bis(diphenylphosphino)-ferrocene]dichloro-palladium(II), a salt such as potassium fluoride or lithium chloride, in a suitable anhydrous solvent such as THF or DMF or ethylene glycol for at temperatures ranging from 25° C. to 125° C. for 2-18 hr yields 6-Aryl-7-alkyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine XI.

[0131] This invention is illustrated by the following Examples. In the Examples, the procedures of Examples 2-28 were carried out by the procedure of Example 1. In the Examples, the procedures of Examples 30-33 were carried out by the procedure of Example 29. In the Examples, the procedures of Examples 35-104 were carried out by the procedure of Example 34. In the Examples, the procedures of Examples 106-112 were carried out by the procedure of Example 105. In the Examples, the procedure of Example 114 was carried out by the procedure of Example 113.

EXAMPLES Example 1

[0132] 6-(3,5-Bis-trifluoromethyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine

[0133] A solution of 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (322 mg, 0.99 mmol) in ethylene glycol dimethyl ether (3.0 mL) and ethanol (3.0 mL)at 25° C. was treated with 3,5-bis(trifluoromethyl)benzene boronic acid (510 mg, 1.98 mmol), a saturated aqueous sodium bicarbonate solution (1.5 mL), and tetrakis(triphenylphosphine)-palladium (o) (115 mg, 0.1 mmol). The resulting mixture was heated to 80° C. for 18 h, cooled, filtered and the isolated solids washed with ethyl acetate. The filtrate was pre-absorbed onto silica gel and purified by flash chromatography (Merck Silica gel 60, 230-400 mesh, 90/10/1 methylene chloride/methanol/ammonium hydroxide) to give 6-(3,5-bis-trifluoromethyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (218 mg, 53.5%) as a yellow solid; EI-HRMS m/e calcd for C₁₈H₁₁F₆N₅ (M+) 411.0918, found 411.0921.

[0134] In an analogous manner, there were obtained:

Example 2

[0135]

[0136] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-ethoxyphenylboronic acid there was produced 6-(3-Ethoxy-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₈H₁₇N₅O (M+H)⁺ at m/z=320.

Example 3

[0137]

[0138] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-ethoxyphenylboronic acid there was produced 6-(2-Ethoxy-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₈H₁₇N₅O (M+H)⁺ at m/z=320.

Example 4

[0139]

[0140] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-nitrophenylboronic acid there was produced 6-(3-Nitro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; EI-HRMS m/e calcd for C₁₆H₁₂N₆O₂ (M+) 320.1022, found 320.1020.

Example 5

[0141]

[0142] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,5-dichlorophenylboronic acid there was produced 6-(2,5-Dichloro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; EI-HRMS m/e calcd for C₁₆H₁₁Cl₂N₅ (M⁺) 343.0391, found 343.0392.

Example 6

[0143]

[0144] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 5-chlorothiophene-2-boronic acid there was produced 6-(5-Chloro-thiophen-2-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; (ES)⁺-HRMS m/e calcd for C₁₄H₁₀ClN₅S (M+H) 316.0418, found 316.0422.

Example 7

[0145]

[0146] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and o-tolylboronic acid there was produced 6-o-Tolyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine as an off-white solid; EI-HRMS m/e calcd for C₁₇H₁₅N₅ (M+H)⁺ 290.1400, found 290.1399.

Example 8

[0147]

[0148] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-aminobenzeneboronic acid there was produced 6-(3-Amino-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₆H₁₄N₆ (M+H)⁺ at m/z =291.

Example 9

[0149]

[0150] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-fluorophenylboronic acid there was produced 6-(4-Fluoro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₆H₁₂FN₅ (M+H)⁺ at m/z=294.

Example 10

[0151]

[0152] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-methylphenylboronic acid there was produced 6-m-Tolyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid;. LRMS for C₁₇H₁₅N₅ (M+H)⁺ at m/z=290

Example 11

[0153]

[0154] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-biphenylphenylboronic acid there was produced 6-Biphenyl-4-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₂₂H₁₇N₅ (M+H)⁺ at m/z =352.

Example 12

[0155]

[0156] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-methyl-3-nitrophenylboronic acid there was produced 6-(4-methyl-3-nitro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₇H₁₄N₆O₂ (M+H)⁺ at m/z=335.

Example 13

[0157]

[0158] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-fluorophenylboronic acid there was produced 6-(3-Fluoro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₆H₁₂FN₅ (M+H)⁺ at m/z=294.

Example 14

[0159]

[0160] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-ethylphenylboronic acid there was produced 6-(4-Ethyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₈H₁₇N₅ (M+H)⁺ at m/z=335.

Example 16

[0161]

[0162] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-tert-butylbenzeneboronic acid there was produced 6-(4-tert-Butyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₂₀H₂₁N₅ (M+H)⁺ at m/z=332.

Example 16

[0163]

[0164] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and (3-isopropylphenyl)boronic acid there was produced 6-(3-Isopropyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt a white solid; LRMS for C₁₉H₁₉N₅ (M+H)⁺ at m/z=318.

Example 17

[0165]

[0166] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and benzo(B)thiophene-2-boronic acid there was produced 6-Benzo[b]thiophen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as white solid; LRMS for C₁₈H₁₃N₅S (M+H)⁺ at m/z=332.

Example 18

[0167]

[0168] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,4-dichlorophenylboronic acid there was produced 6-(2,4-Dichloro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₆H₁₁Cl₂N₅ (M+H)⁺ at m/z=344.

Example 19

[0169]

[0170] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 1-naphthaleneboronic acid there was produced 6—Naphthalen-1-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₂₀H₁₅N₅ (M+H)⁺ at m/z=326.

Example 20

[0171]

[0172] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3,5-dichlorophenylboronic acid there was produced 6-(3,5-Dichloro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₆H₁₁Cl₂N₅ (M+H)⁺ at m/z=344.

Example 21

[0173]

[0174] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and naphthalene-2-boronic acid there was produced 6—Naphthalen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₂₀H₁₅N₅ (M+H)⁺ at m/z=326.

Example 22

[0175]

[0176] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-chlorophenylboronic acid there was produced 6-(2-Chloro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₆H₁₂ClN₅ (M+H)⁺ at m/z=310.

Example 23

[0177]

[0178] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,4-dimethoxyphenylboronic acid there was produced 6-(2,4-Dimethoxy-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₈H₁₇N₅O₂ (M+H)⁺ at m/z=336.

Example 24

[0179]

[0180] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 5-acetyl-2-thiopheneboronic acid there was produced 1-[5-(1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-thiophen-2-yl]-ethanone trifluoro-acetic acid salt as a white solid; LRMS for C₁₆H₁₃N₅OS (M+H)⁺ at m/z=324.

Example 25

[0181]

[0182] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-formylphenylboronic acid there was produced 3-(1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-benzaldehyde as a yellow solid; (ES)⁺-HRMS m/e calcd for C₁₇H₁₃N₅O (M+H)⁺ 304.1193, found 304.1195.

Example 26

[0183]

[0184] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 5-chloro-2-methoxyphenylboronic acid there was produced 6-(5-Chloro-2-methoxy-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₄ClN₅O (M+H)⁺ at m/z=340.

Example 27

[0185]

[0186] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and (3-acetylaminophenyl)boronic acid there was produced N-[3-(1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-acetamide trifluoro-acetic acid salt as a white solid; LRMS for C₁₈H₁₆N₆O (M+H)⁺ at m/z=333.

Example 28

[0187]

[0188] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-(trifluoromethylbenzene)boronic acid there was produced 6-(2-Trifluoromethyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine as a light brown solid; LRMS for C₁₇H₁₂F₃N₅ (M+H)⁺ at m/z=344.

Example 29

[0189] 3-[2-(1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-propionic Acid

[0190] A mixture of 3-(2-bromo-phenyl)-propionic acid (458 mg, 2.0 mmol), 4,4,5,5,4′,4′,5′,5′-octamethyl-[2,2′]bi[[1,3,2]dioxaborolanyl](558 mg, 2.20 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II) (132 mg, 0.18 mmol), and potassium acetate (589 mg, 6.0 mmol) was heated to 95° C. for 2 d. The resulting mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with a saturated aqueous sodium chloride solution, filtered through a pad of silca gel and sodium sulfate, and concentrated in vacuo to afford 3-[2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid. A solution of 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (prepared as in Example 1, 100 mg, 0.31 mmol), 3-[2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid (102 mg, 0.37 mmol), tetrakis(triphenylphosphine)palladium(o) (71 mg, o.o6 mmol) in a 2.0M aqueous sodium carbonate solution (0.5 mL), ethanol (1.5 mL), and ethylene glycol dimethyl ether (1.5 mL) was heated to 95° C. for 18 h. The resulting mixture was cooled to 25° C., dissolved in methanol and tetrahydrofuran, and filtered through a pad of silica gel and sodium sulfate. The filtrate was concentrated in vacuo. HPLC purification (Shimadzu HPLC, ODSA column from Medchem, 2×10 cm, 10 micro, 10-90% CH₃CN/H2O with 0.1% TFA.) afforded 3-[2-(1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-propionic acid (12.5 mg, 12.1%); LRMS for C₁₉H₁₇N₅O₂ (M+H)⁺ at m/z=348.

[0191] In an analogous manner, there were obtained:

Example 30

[0192]

[0193] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and [3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid there was produced [3-(1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-acetic acid; LRMS for C₁₈H₁₅N₅O₂ (M+H)⁺ at m/z=334.

Example 31

[0194]

[0195] From 6-iodo-₇H-pyrrolo[3,2-f]quinazoline-1,3-diamine and [4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid there was produced [4-(1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-acetic acid; LRMS for C₁₈H₁₅N₅O₂ (M+H)⁺ at m/z=334.

Example 32

[0196]

[0197] From 6-iodo-₇H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-[3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid there was produced 3-[3-(1,3-Diamino-₇H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-propionic acid; LRMS for C₁₉H₁₇N₅O₂ (M+H)⁺ for m/z=348.

Example 33

[0198]

[0199] From 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid there was produced 3-[4-(1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-propionic acid; LRMS for C₁₉H₁₇N₅O₂ (M+H)⁺ at m/z=348.

Example 34

[0200]

[0201] A solution of 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (1.68 g, 5.00 mmol) in ethylene glycol dimethyl ether (10 mL) at 25° C. was treated with 2,6-dimethylbenzene boronic acid (1.50 g, 10.0 mmol) in ethanol (10 mL), sodium bicarbonate (2.84 g, 26.80 mmol), and tetrakis(triphenylphosphine)-palladium (o) (3.31 g, 2.86 mmol). The resulting mixture was heated to 80° C. for 3 h. The resulting mixture was filtered through a pad of celite and the filtrate diluted with water (100 mL). This solution was extracted with a 95/5/0.5 solution of methylene chloride/methanol/ammonium hydroxide (3×100 mL) and the combined organic layers dried over magnesium sulfate, filtered, and concentrated in vacuo. Flash chromatography (Merck Silica gel 60, 230-400 mesh, 90/5/0.5 methylene chloride/methanol/ammonium hydroxide) afforded 6-(2,6-dimethyl-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (100 mg, 6.34%) as an off-white solid; EI-HRMS m/e calcd for C₁₉H₁₉N₅ (M+) 317.1640, found 317.1632.

[0202] In an analogous manner, there were obtained:

Example 35

[0203]

[0204] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3,4-methylenedioxyphenylboronic acid there was produced 6-Benzo[1,3]dioxol-5-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₈H₁₅N₅O₂ (M+H)⁺ at m/z=334.

Example 36

[0205]

[0206] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-aminobenzeneboronic acid there was produced 6-(3-Amino-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₇H₁₆N₆ (M+H)⁺ at m/z=305.

Example 37

[0207]

[0208] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-fluorophenylboronic acid there was produced 6-(4-Fluoro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₇H₁₄FN₅ (M+H)⁺ at m/z=308.

Example 38

[0209]

[0210] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-methylphenylboronic acid there was produced 7-Methyl-6-m-tolyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₈H₁₇N₅ (M+H)⁺ at m/z=304.

Example 39

[0211]

[0212] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-biphenylboronic acid there was produced 6-Biphenyl-4-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₂₃H₁₉N₅ (M+H)⁺ at m/z=366.

Example 40

[0213]

[0214] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-methyl-3-nitrophenylboronic acid there was produced 7-methyl-6-(4-methyl-3-nitrophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₈H₁₆N₆O₂ (M+H)⁺ for m/z=349.

Example 41

[0215]

[0216] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-fluorophenylboronic acid there was produced 6-(3-Fluoro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₇H₁₄FN₅ (M+H)⁺ at m/z=308.

Example 42

[0217]

[0218] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-ethylphenylboronic acid there was produced 6-(4-Ethyl-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₉H₁₉N₅ (M+H)⁺ at m/z=318.

Example 43

[0219]

[0220] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and (3-isopropylphenyl)boronic acid there was produced 6-(3-Isopropyl-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₂₀H₂₁N₅ (M+H)⁺ at m/z=332.

Example 44

[0221]

[0222] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and benzo[B]thiphene-2-boronic acid there was produced 6-Benzo[b]thiophen-2-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for Cl₉H₁₅N₅S (M+H)⁺ at m/z=346.

Example 45

[0223]

[0224] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,4-dichlorophenylboronic acid there was produced 6-(2,4-Dichloro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₇H₁₃Cl₂N₅ (M+H)⁺ at m/z=358.

Example 46

[0225]

[0226] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3diamine and 1-naphthaleneboronic acid there was produced 7-Methyl-6-naphthalen-1-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₂₁H₁₇N₅ (M+H)⁺ at m/z=340.

Example 47

[0227]

[0228] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3,5-dichlorophenylboronic acid there was produced 6-(3,5-Dichloro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₇H₁₃C₁₂N₅ (M+H)⁺ at m/z=358.

Example 48

[0229]

[0230] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and (3-acetylaminophenyl)boronic acid there was produced N-[3-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-acetamide trifluoro-acetic acid salt as a white solid; LRMS for C₁₉H₁₈N₆O (M+H)⁺ at m/z=347.

Example 49

[0231]

[0232] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and naphthalene-2-boronic acid there was produced 7-Methyl-6-naphthalen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₂₁H₁₇N₅ (M+H)⁺ at m/z=340.

Example 50

[0233]

[0234] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-chlorophenylboronic acid there was produced 6-(2-Chloro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₇H₁₄ClN₅ (M+H)⁺ at m/z=324.

Example 51

[0235]

[0236] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,4-dimethoxyphenylboronic acid there was produced 6-(2,4-Dimethoxy-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a white solid; LRMS for C₁₉H₁₉N₅O₂ (M+H)⁺ at m/z=350.

Example 52

[0237]

[0238] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-acetylphenylboronic acid there was produced 1-[3-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-ethanone trifluoro-acetic acid salt as a white solid; LRMS for C₁₉H₁₇N₅O (M+H)⁺ at m/z=332.

Example 53

[0239]

[0240] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 5-acetyl-2-thiopheneboronic acid there was produced 1-[5-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-thiophen-2-yl]-ethanone trifluoro-acetic acid salt as a white solid; LRMS for C₁₇H₁₅N₅OS (M+H)⁺ at m/z=338.

Example 54

[0241]

[0242] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and (3-hydroxymethylphenyl)boronic acid there was produced [3-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-methanol trifluoro-acetic acid salt; LRMS for C₁₈H₁₇N₅O (M+H)⁺ at m/z=320.

Example 55

[0243]

[0244] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,3-dimethylphenylboronic acid there was produced 6-(2,3-Dimethyl-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₉H₁₉N₅ (M+H)⁺ at m/z=318.

Example 56

[0245]

[0246] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,5-difluorophenylboronic acid there was produced 6-(2,5-Difluoro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₃F₂N₅ (M+H)⁺ at m/z=326.

Example 57

[0247]

[0248] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 5-fluoro-2-methoxyphenylboronic acid there was produced 6-(5-Fluoro-2-methoxy-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₈H₁₆FN₅O (M+H)⁺ at m/z=338.

Example 58

[0249]

[0250] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,5-dimethoxyphenylboronic acid there was produced 6-(2,5-Dimethoxy-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS m/z calcd for C₁₉H₁₉N₅O₂ (M+H)⁺ at m/z=350.

Example 59

[0251]

[0252] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-acetylphenylboronic acid there was produced 1-[2-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-ethanone trifluoro-acetic acid salt; LRMS for C₁₉H₁₇N₅O (M+H)⁺ at m/z=332.

Example 60

[0253]

[0254] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 5-chlorothiophene-2-boronic acid there was produced 6-(5-Chloro-thiophen-2-yl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₅H₁₂ClN₅S (M+H)⁺ at m/z=330.

Example 61

[0255]

[0256] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and furan-2-boronic acid there was produced 6-Furan-2-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₅H₁₃N₅O (M+H)⁺ at m/z=280.

Example 62

[0257]

[0258] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 5-methylthiophene-2-boronic acid there was produced 7-Methyl-6-(5-methyl-thiophen-2-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine as an off-white solid; EI-HRMS m/e calcd. for C₁₆H₁₅N₅S (M+H)⁺ 310.1121, found 310.1125.

Example 63

[0259]

[0260] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-acetylphenylboronic acid there was produced 1-[4-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-ethanone trifluoro-acetic acid salt; LRMS for C₁₉H₁₇N₅O (M+H)⁺ at m/z=332.

Example 64

[0261]

[0262] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3,4-dimethoxyphenylboronic acid there was produced 6-(3,4-Dimethoxy-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₉H₁₉N₅O₂ (M+H)⁺ at m/z=350.

Example 65

[0263]

[0264] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-(trifluoromethoxy)benzeneboronic acid there was produced 7-Methyl-6-(4-trifluoromethoxy-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₈H₁₄F₃N₅O (M+H)⁺ at m/z=374.

Example 66

[0265]

[0266] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,6-difluorophenylboronic acid there was produced 6-(2,6-Difluoro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₃F₂N₅ (M+H)⁺ at m/z=326.

Example 67

[0267]

[0268] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3,4-dichlorophenylboronic acid there was produced 6-(3,4-Dichloro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₃Cl₂N₅ (M+H)⁺ at m/z=358.

Example 68

[0269]

[0270] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-bromophenylboronic acid there was produced 6-(4-Bromo-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₄BrN₅ (M+H)⁺ at m/z=368.

Example 69

[0271]

[0272] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-nitrophenylboronic acid there was produced 7-methyl-6-(3-nitro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₄N₆O₂ (M+H)⁺ at m/z=335.

Example 70

[0273]

[0274] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-(ethylthio)phenylboronic acid there was produced 6-(4-Ethylsulfanyl-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₉H₁₉N₅S (M+H)⁺ at m/z=350.

Example 71

[0275]

[0276] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-(methylthio)phenylboronic acid there was produced 7-Methyl-6-(4-methylsulfanyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₈H₁₇N₅S (M+H)⁺ at m/z=336.

Example 72

[0277]

[0278] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-methylphenylboronic acid there was produced 7-Methyl-6-p-tolyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₈H₁₇N₅ (M+H)⁺ at m/z=304.

Example 73

[0279]

[0280] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-chlorophenylboronic acid there was produced 6-(4-Chloro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₄ClN₅ (M+H)⁺ at m/z=324.

Example 74

[0281]

[0282] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3,5-dimethylisoxazole-4-boronic acid there was produced 6-(3,5-Dimethyl-isoxazol-4-yl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₆H₁₆N₆O (M+H)⁺ at m/z=309.

Example 75

[0283]

[0284] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and benzothiophene-7-boronic acid there was produced 6-(3,5-6-Benzo[b]thiophen-7-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₉H₁₅N₅S (M+H)⁺ at m/z=346.

Example 76

[0285]

[0286] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and phenoxathin-4-boronic acid there was produced 7-Methyl-6-phenoxathiin-4-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₂₃H₁₇N₅OS (M+H)⁺ at m/z=412.

Example 77

[0287]

[0288] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-fluorophenylboronic acid there was produced 6-(2-Fluoro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₄FN₅ (M+H)⁺ at m/z=308.

Example 78

[0289]

[0290] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,4-difluorobenzeneboronic acid there was produced 6-(2,4-Difluoro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₃F₂N₅ (M+H)⁺ at m/z=326.

Example 79

[0291]

[0292] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,5-dimethylphenylboronic acid there was produced 6-(2,5-Dimethyl-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₉H,₉N₅ (M+H)⁺ at m/z=318.

Example 80

[0293]

[0294] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,3-dichlorophenylboronic acid there was produced 6-(2,3-Dichloro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₃Cl₂N₅ (M+H)⁺ at m/z=358.

Example 81

[0295]

[0296] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-formyl-3-thiopheneboronic acid there was produced 3-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-thiophene-2-carbaldehyde trifluoro-acetic acid salt; LRMS for C₁₆H₁₃N₅OS (M+H)⁺ at m/z=324.

Example 82

[0297]

[0298] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and (4-hydroxyphenyl)boronic acid there was produced 4-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenol trifluoro-acetic acid salt; LRMS for C₁₇H₁₅N₅O (M+H)⁺ at m/z=306.

Example 83

[0299]

[0300] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 1-benzothiophen-3-ylboronic acid there was produced 6-Benzo[b]thiophen-3-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₉H₁₅N₅S (M)+at m/z=345.

Example 84

[0301]

[0302] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and (2-nitrophenyl)boronic acid there was produced 7-methyl-6-(2-nitro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₄N₆O₂ (M+H)⁺ at m/z=335.

Example 85

[0303]

[0304] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 5-isopropyl-2-methoxybenzeneboronic acid there was produced 6-(5-Isopropyl-2-methoxy-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₂₁H₂₃N₅O (M+H)⁺ at m/z=362.

Example 86

[0305]

[0306] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and (3-hydroxyphenyl)boronic acid there was produced 3-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenol trifluoro-acetic acid salt; LRMS for C₁₇H₁₅N₅O (M+H)⁺ at m/z=306.

Example 87

[0307]

[0308] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-(phenoxy)phenylboronic acid there was produced 7-Methyl-6-(2-phenoxy-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₂₃H₁₉N₅O (M+H)⁺ at m/z=382.

Example 88

[0309]

[0310] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-chlorophenylboronic acid there was produced 6-(3-Chloro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₄ClN₅ (M+H)⁺ at m/z=324.

Example 89

[0311]

[0312] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and o-tolylboronic acid there was produced 7-Methyl-6-o-toIyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₈H₁₇N₅ (M+H)⁺ at m/z=304.

Example 90

[0313]

[0314] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-vinylphenylboronic acid there was produced 7-Methyl-6-(4-vinyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₉H₁₇N₅ (M+H)⁺ at m/z=316.

Example 91

[0315]

[0316] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-ethoxyphenylboronic acid there was produced 6-(4-Ethoxy-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₉H₁₉N₅O (M+H)⁺ at m/z=334.

Example 92

[0317]

[0318] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-chloro-4-fluorophenylboronic acid there was produced 6-(3-Chloro-4-fluoro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₃ClFN₅ (M+H)⁺ at m/z=342.

Example 93

[0319]

[0320] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-methoxyphenylboronic acid there was produced 6-(4-Methoxy-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₈H₁₇N₅O (M+H)⁺ at m/z=320.

Example 94

[0321]

[0322] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 4-bromo-2-fluorobenzeneboronic acid there was produced 6-(4-Bromo-2-fluoro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₇H₁₃BrFN₅ (M+H)⁺ at m/z=386.

Example 95

[0323]

[0324] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2,6-dimethoxyphenylboronic acid there was produced 6-(2,6-Dimethoxy-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt; LRMS for C₁₉H₁₉N₅O₂ (M+H)⁺ at m/z=350.

Example 96

[0325]

[0326] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-tert-butoxycarbonyl-4-methoxyphenylboronic acid there was produced 2-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-5-methoxy-benzoic acid trifluoro-acetic acid salt; LRMS for C₁₉H₁₇N₅O₃ (M+H)⁺ at m/z=364.

Example 97

[0327]

[0328] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 5-methoxy thiopheneboronic acid there was produced 6-(5-Methoxy-thiophen-2-yl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine as a light yellow solid; EI-HRMS m/e calcd for C₁₆H₁₅N₅OS (M+) 325.0997, found 325.0994.

Example 98

[0329]

[0330] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-methoxyphenylboronic acid there was produced 6-(2-Methoxy-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine as a light brown solid; LRMS for C₁₈H₁₇N₅O (M+H)⁺ at m/z=320.

Example 99

[0331]

[0332] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and thiophene-2-boronic acid there was produced 7-Methyl-6-thiophen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine as a light yellow solid; LRMS for C₁₅H₁₃N₅S (M+Na)⁺ at m/z=318.

Example 100

[0333]

[0334] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and benzo[B]furan-2-boronic acid there was produced 6-Benzofuran-2-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine as a yellow solid; LRMS for C₁₉H₁₅N₅O (M+H)⁺ at m/z=330.

Example 101

[0335]

[0336] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-(trifluoromethyl)benzeneboronic acid there was produced 7-Methyl-6-(2-trifluoromethyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine as a yellow solid; LRMS for C₁₈H₁₄F₃N₅ (M+H)⁺ at m/z=358.

Example 102

[0337]

[0338] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and [3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid there was produced [3-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-acetic acid; LRMS for C₁₉H₁₇N₅O₂ (M+H)⁺ at m/z=348.

Example 103

[0339]

[0340] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-[2-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid there was produced 3-[2-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-propionic acid; LRMS for C₂₀H₁₉N₅O₂ (M+H)⁺ at m/z=362.

Example 104

[0341]

[0342] From 6-iodo-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-[3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid there was produced 3-[3-(1,3-Diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-propionic acid; LRMS for C₂₀H₁₉N₅O₂ (M+H)⁺ at m/z=362.

Example 105

[0343] 7-Methanesulfonyl-6-thiophen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine Trifluoro-acetic Acid Salt

[0344] To a slurry of 6-Thiophen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (example 100), prepared as described in example 1 from 6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine VI and 2-thiopheneboronic acid, (50 mg, 0.178 mmole) in anhydrous DMF (3 ml) at room temperature was added sodium hydride (60% in mineral oil, 8 mg, 0.20 mmole) and the mixture was stirred at room temperature for 45 minutes. The above mixture was cooled in an ice bath, methanesulfonyl chloride was slowly added dropwise (0.016 ml, 0.207 mmole) and stirred at 0° C. for 30 minutes. The mixture was then warmed up to room temperature and stirred overnight. Additional amounts of sodium hydride (8 mg) and methanesulfonyl chloride (0.016 ml) was added the next day to drive the reaction to completion and the mixture was stirred at room temperature for an additional 20 hours. The mixture was evaporated to dryness and the crude mixture was purified by reversed phase HPLC to give 7-Methanesulfonyl-6-thiophen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a light brown solid; LRMS m/z calcd for C₁₅H₁₃N₅O₂S₂ (M+H)⁺ at m/z=360.

Example 106

[0345]

[0346] From 2-(1,3-Diamino-6-iodo-pyrrolo[3,2-f]quinazolin-7-yl)-ethanol and 2-(trifluoromethyl)benzeneboronic acid there was produced 2-[1,3-Diamino-6-(2-trifluoromethyl-phenyl)-pyrrolo[3,2-f]quinazolin-7-yl]-ethanol trifluoro-acetic acid salt as an off-white solid; LRMS for C₁₉H₁₆F₃N₅O (M+H)⁺ at m/z=388.

Example 107

[0347]

[0348] From (1,3-Diamino-6-iodo-pyrrolo[3,2-f]quinazolin-7-yl)-acetic acid and 2-(trifluoromethyl)benzeneboronic acid there was produced [1,3-Diamino-6-(2-trifluoromethyl-phenyl)-pyrrolo[3,2-f]quinazolin-7-yl]-acetic acid trifluoro-acetic acid salt as an off-white solid; LRMS for C₁₉H₁₄F₃N₅O₂ (M+H)⁺ at m/z=402.

Example 108

[0349]

[0350] From (1,3-Diamino-6-iodo-pyrrolo[3,2-f]quinazolin-7-yl)-acetic acid and thiophene-2-boronic acid there was produced (1,3-Diamino-6-thiophen-2-yl-pyrrolo[3,2-f]quinazolin-7-yl)-acetic acid trifluoro-acetic acid salt as an off-white solid; LRMS for C₁₆H₁₃N₅O₂S (M+H)⁺ at m/z=340.

Example 109

[0351]

[0352] From 7-(2-Benzyloxy-ethyl)-6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 2-(trifluoromethyl)benzeneboronic acid there was produced 7-(2-Benzyloxy-ethyl)-6-(2-trifluoromethyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt as a light brown solid; LRMS for C₂₆H₂₂F₃N₅O (M+H)⁺ at m/z=478.

Example 110

[0353]

[0354] From 2-(1,3-Diamino-6-iodo-pyrrolo[3,2-f]quinazolin-7-yl)—N,N-diethyl-acetamide and 3-methoxyphenylboronic acid there was produced 2-[1,3-Diamino-6-(3-methoxy-phenyl)-pyrrolo[3,2-f]quinazolin-7-yl]—N,N-diethyl-acetamide as a yellow solid; LRMS for C₂₃H₂₆N₆O₂ (M+H)⁺ at m/z=419.

Example 111

[0355]

[0356] From 7-Ethyl-6-iodo-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and thiophene-2-boronic acid there was produced 7-Ethyl-6-thiophen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine as an off-white solid; ¹H NMR (DMSO-d₆, 300 MHz) δ 7.69 (d, J=5.13 Hz, 1H), 7.49 (d, J=2.56 Hz, 1H), 7.27 (m, 1H), 7.18 (m, 1H), 7.14 (d, J=2.56 Hz, 1H), 6.91 (s, 1H), 6.81 (broad S, 2H), 5.82 (broad S, 2H), 3.82 (q, J=6.96 Hz, 2H), 0.99 (t, J=6.96 Hz, 3H).

Example 112

[0357]

[0358] From 6-Iodo-7-(2-methoxy-ethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and 3-methoxyphenylboronic acid there was produced 7-(2-Methoxy-ethyl)-6-(3-methoxy-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine as a light-brown solid; LRMS for C₂₀H₂₁N₅O₂ (M+H)⁺ at m/z=364.

[0359] Scheme 5 is directed to the synthesis of 8 methyl derivatives.

Example 113

[0360] 8-Methyl-6-thiophen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine Trifluoroacetic Acid Salt

[0361] To a cooled (0-10 C.) mixture of concentrated nitric acid (12 mL) and concentrated sulfuric acid (40 mL) was added 1-acetyl-2-methyl-indoline XII (12.5 g, 0.0713 moles), prepared by an analgous method to that described in Chem.Ber.; 14; 1881; 890, in small portions so that the internal temperature of the reaction remained between 10-20° C. The resulting mixture was allowed to stir at 5-10° C. overnight. The mixture was poured slowly into 300 mL of cold water and the precipitate that formed was collected by filtration, washed with water and redissolved in an ethanol-6N HCl solution and warmed to reflux for 30 minutes. The resulting solution was concentrated, EtOAc was added and the Ph of the solution adjusted to 10. The organic phase was separated and dried over MgSO₄. The mixture was filtered, and evaporated and the crude material purified by column chromatography (50% EtOAc-Hexane) to give 3.31 g, 26% of 2-methyl-5-nitro-2,3-dihydro-1H-indole XIII: LRMS for C₉H₁₀N₂O₂ (M+H)⁺ at m/z=179.

[0362] A mixture of silver sulfate (4.92 g, 0.0157 mol) and iodine (4 g, 0.0.0157 mol) in N,N-dimethylformamide (50 mL) and ethanol (100 mL) was treated with 2-methyl-5-nitro-2,3-dihydro-1H-indole XIII (3.31 g, 0.015 mol) and the resulting mixture was stirred at 25° C. for 30 min before an additional 1 g of iodine was added and the stirring continued for 2 h. The resulting reaction mixture was filtered and the solids washed with ethyl acetate before being concentrated in vacuo to a volume of approximately 50 mL. This solution was treated with a 1.0N aqueous sodium thiosulfate solution (100 mL) and a saturated aqueous sodium chloride solution (200 mL). The resulting precipitate was collected by filtration, washed with water and petroleum ether, and dried in vacuo to 7-iodo-2-methyl-5-nitro-2,3-dihydro-1H-indole XIV as a yellow solid: LRMS for C₉H₉IN₂O₂ (M+H)⁺ at m/z=305.

[0363] A solution of 7-iodo-2-methyl-5-nitro-2,3-dihydro-1H-indole XIV (4.75 g, 0.0156 mol) in methanol (150 mL) at 25° C. was treated with a solution of ammonium chloride (5.22 g, 0.0976 mol) in water (150 mL) and iron powder (3 g, 0.0534 mol). The mixture was heated to 100° C. under a nitrogen atmosphere for 6 h. The reaction mixture was filtered hot through a pad of celite and washed with hot methanol. The filtrate was concentrated in vacuo and the residue partitioned between methylene chloride and water. The layers were separated and the pH of the aqueous layer was adjusted to pH=10 with ammonium hydroxide. The aqueous layer was extracted with methylene chloride and the combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to a volume of 50 mL. The resulting solution was treated with a 4.0M aqueous hydrochloric acid solution in dioxane and then stirred at 25° C. for 1 h. The precipitate was collected by filtration and washed with methylene chloride and petroleum ether to afford 7-iodo-2-methyl-1H-indol-5-ylamine hydrochloride XV (4.37 g, 81%) as a gray solid: LRMS for freebase C₉H₁₁IN₂ (M+H)⁺ at m/z=275.

[0364] A solution of 7-iodo-2-methyl-1H-indol-5-ylamine hydrochloride XV (4.3 g, 12.39 mmol) in methanol (200 mL) at 25° C. was treated with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (2.8 g, 12.39 mmol) in portions. The resulting dark solution was concentrated in vacuo and partitioned between water and methylene chloride, the pH was adjusted to 10 by the addition of with ammonium hydroxide, the organic layer separated and filtered and the aqueous layer extracted 3×100 mL with methylene chloride. The organic layers were combined, dried over magnesium sulfate and charcoal. The mixture was filtered and concentrated to 100 mL in volume before 20 mL of a 4.0 M HCL in dioxane solution was added. The resulting mixture was stirred at room temperature for 1 h and the precipitate formed was isolated by filtration, washed well with ether and dried to give 7-iodo-2-methyl-1H-indol-5-ylamine hydrochloride XVI (1.94 g, 58%) as a grey solid: LRMS for freebase C₉H₉IN₂ (M+H)⁺ at m/z=273.

[0365] A solution of 7-iodo-2-methyl-1H-indol-5-ylamine hydrochloride XVII (1.9 g, 6.158 mmol) in N,N-dimethylformamide (30 mL) at 25° C. was treated with sodium dicyanamide (1.37 g, 15.397 mmol) and then warmed to 45° C. for 4 h. The resulting mixture filtered and concentrated in vacuo and the residue treated with water (20 mL). The resulting mixture was allowed to stand at 25° C. for 2.5 h during which time a solid formed. The solid was collected by filtration and washed with water, resuspended in methanol, filtered and dried to give N″-cyano—N-(7-iodo-2-methyl-1H-indol-5-yl)guanidine XVIII (0.88 g, 42%) as a light grey solid: LRMS for C₁₁H₁₀IN₅ (M−H)⁺ at m/z=338.

[0366] A solution of N″-cyano-N-(7-iodo-2-methyl-1H-indol-5-yl)guanidine XVIII (0.86 g, 2.54 mmol) in 2-methoxyethyl ether (20 mL) was heated to 175° C. for 28 h. The reaction mixture was cooled to 25° C. and the solid formed was removed by filtration and washed with methanol. The filtrate was concentrated in vacuo and the residue triturated with methanol and ether to give a brown solid which was isolated by filtration and dried to give 6-iodo-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine XIX (120 mg, 14%) as a brown solid: LRMS for C₁₁H₁₀IN₅ (M+H)⁺ at m/z=340.

[0367] A solution of 6-iodo-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine XIX (20 mg, 0.06 mmol) in ethylene glycol dimethyl ether (5.0 mL) and ethanol (2.5 mL) at 25° C. was treated with 2-thiopheneboronic acid (11 mg, 0.09 mmol), a 2 M aqueous sodium carbonate solution (2.5 mL), and tetrakis(triphenylphosphine)-palladium (o) (0.3 mg, 0.0026 mmol). The resulting mixture was heated to 80° C. for 3 h, cooled and pre-absorbed onto silica gel and purified by flash chromatography (Merck Silica gel 60, 230-400 mesh, 90/10/1 methylene chloride/methanol/ammonium hydroxide) followed by reversed phase HPLC (Zorbax 21.2×100 mmSB C18 column, 15 min 95/5 to 5/95 water/acetonitrile 0.075% TFA gradient) to afford 8-Methyl-6-thiophen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt XX (4 mg, 25%) as a lyophuilized solid, LRMS for freebase C₁₅H₁₃N₅S₂ (M+H)⁺ at m/z=296.

[0368] In an analogous manner, there were obtained:

Example 114

[0369]

[0370] From 6-iodo-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine 2-(trifluoromethylbenzene)boronic acid 8-Methyl-6-(2-trifluoromethyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine as a lyophilized solid; LRMS for C₁₈H₁₄F₃N₅ (M+H)⁺ at m/z=358.

Example 115

[0371] In vitro Inhibition of PTP1B

[0372] Enzymes

[0373] Human PTP1B (1-321) was cloned from a human cDNA library using conventional molecular biology techniques. The cDNA sequence was identical to the published human PTP1B sequence (Accession number M33689). The protein was expressed and purified from E. coli as described by Barford D. et.al, J. Mol Biol (1994) 239,726-730).

Example 116

[0374] PTPase Assays

[0375] The measurement of PTPase activity was carried out using one of two methods:

[0376] The first method for the measurement of PTP1B inhibitory activity a tyrosine phosphorylated peptide based on the amino acid sequence of insulin receptor tyrosine autophosphorylation site 1146 (TRDI(pY)E) was used as substrate. The reaction conditions were as follows:

[0377] PTP1B (O.5-2nM ) was incubated with compound for 15 min in buffer containing 37.5 mM Bis-Tris buffer pH 6.2, 140 mMNaCl, 0.05% BSA and 2 mM DTT. The reaction was started by the addition of 50 μM substrate. After 20 min at room temperature (22-25° C.) the reaction was stopped with KOH and the amount of free phosphate measured using Malachite Green as previously described. (Harder et al. 1994 Biochem J. 298; 395).

[0378] The second method was used for the measurement of general PTPase inhibitory activity across a panel of PTPases the substrate (6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP; from Molecular Probes) was used at the Km for each enzyme. The buffer conditions were identical as in the Malachite Green assay. The reaction was stopped with KOH. In this case the dephosphoryated product becomes fluorescent and the fluorescence read. (Excitiation:360 mM/Emmission: 460 nM).

[0379] For kinetic experiments the same buffer conditions were used except that the reaction was started using enzyme and the reaction stopped after 10 minutes.

[0380] The IC₅₀ values (in μM) for the PTP1B inhibitory activity of the compounds in range of 5.20 μM to 96.3 μM. The most preferred compounds show an IC₅₀ of <30.0 μM.

[0381] Examples of the some compounds with its corresponding IC₅₀ values are Example IC₅₀ (μM) 2 23.79 4 89.52 6 29.22 8 24.11

Example 117

[0382] Glucose Uptake Assay

[0383] the day before the assay the SKMC media was changed to high glucose DMEM, 25 mM Hepes, pH 7.0 and 2% Charcoal/dextran treated FBS for 19 hours.

[0384] On the morning of the assay, cells were starved for max. 2 hours in low glucose (5.5 mM glucose) DMEM 25 mM Hepes, pH 7.0 and 0.5% BSA. The starvation medium was removed and replaced with test medium (150 mMNaCl, 25mM Hepes, pH 7.0) containing either 1% DMSO, or test compound diluted in DMSO or Porcine Insulin to a final concentrations of 1, 0.1, 0.05, 0.01 and 0.01 μM. Each assay point was performed in triplicate. The cells were incubated for 45 min at 37° C. 10 μM Cytochalasin B (CB) was added to appropriate wells to stop the active glucose transport (i.e. GLUT 1 & 4). At this point 2-Deoxy-D(U-14C) glucose (Amersham, Code CFB195, 200 uCi/ml) was added to all wells to a final concentration of 0.8 μCi/ml. The cells were incubated for an additional 45 minutes at 37° C. in an incubator. Cells were then very gently washed for three times in PBS (RT). The cells were then lysed with the addition of 0.05% NaOH solution for 20 min at RT. The lysate was transferred to a scintillation vial containing 5 ml of scintillation fluid and counted in a Beckman LS6500 Scintillation counter. Analysis of results: The counts obtained with CB (passive glucose transport values) were subtracted from every value obtained with PI (or compounds) in order to evaluate only active glucose transport. Fold increase was calculated by dividing values in the presence of PI (or compounds) by the value obtained in the presence of DMSO (control). Compounds were considered to be active when they increase glucose uptake at least 25% of the Porcine Insulin response at 0.05 μM.

Example 118

[0385] In vivo Inhibition of PTP1B: Effects of Compounds on Blood Glucose Levels in Mouse Model

[0386] To measure the anti-diabetic effect compounds were tested in well established rodent in vivo models of type 2 diabetes and obesity.

[0387] Diet Induced Obese C₅₇BL6/J Mice (DIO Mice)

[0388] Mice that have type 2 diabetes were be generated by maintaining them on a high fat diet for a 4-6 months (Diabetes vol. 37 Sept 1988). Male C57B16/J mice (age 3-4 weeks) were placed on high fat diet for 4-6 months. At this time, they were hyperglycemic and hyperinsulinemic and weighed 40-50 g. DIO mice (n=10) were weighed and fasted for a two hour period prior to oral treatment. Immediately prior to dosing a pre-dose blood glucose reading was taken by snipping off a portion of the tail and collecting blood from the tail vein. Mice were treated either with a single dose of compound (acute) or once a day for 5 days (sub-chronic). For the acute studies glucose was generally measured at 2 h, 4 h, 6 h, 8 h post treatment. Compounds were considered active if they showed a statistically significant (p≦0,05) glucose lowering (>15%) compared to the vehicle treated animals.

[0389] For sub-chronic (5 day) studies mice were dosed once a day by gavage as described above. On day five, glucose was measured prior to dosing (o time) and 2 hours after dosing. Insulin and triglycerides were measured at 2 hour post dose. Compounds were considered active if they showed a statistically significant (p≦0,05) glucose, insulin and triglyceride lowering compared to the vehicle treated animals. 

What is claimed is:
 1. A phenyl ring containing the compound of the formula:

wherein R₁ is selected from hydrogen and lower alkyl; R₂ is selected from the group consisting of hydrogen, lower alkyl,

R₃ and R₄ are independently selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkoxy, hydroxy lower alkyl, perfluoroloweralklyl, nitro, halo, lower alkanoyl, —N R₅R₆, R₇S—,

phenyl, hydroxy, perfluoroloweralkoxy, and phenoxy, or R₃ and R₄ when present on adjacent carbon atoms on the phenyl ring can be taken together to form a lower alkylenedioxy bridge or taken together with their adjacent carbon atoms to form an aromatic ring system fused to the phenyl ring, said aromatic ring system containing one or two aromatic rings with one of said rings being either an aromatic or heteroaromatic ring; R₅ and R₆ are independently selected from hydrogen and lower alkyl; R₁₂ is selected from the group consisting of hydrogen, benzyl, phenyl and lower alkyl; R₇ is lower alkyl; R₁₃ is selected from the group consisting of hydrogen, lower alkyl, benzyl and phenyl; R₁₀, R₁₁ and R₁₂ are independently selected from hydrogen and lower alkyl; and m, n, o and v are independent integers selected from 0 to 4 or pharmaceutically acceptable salts thereof.
 2. The compound of claim 1 wherein R₁ is hydrogen and R₃ and R₄ are substituted on adjacent carbon atoms and form a lower alkylene dioxy bridge and R₂ is selected from lower alkyl and hydrogen.
 3. The compound of claim 2 wherein said compound is 6-benzo[1,3]dioxol-5-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 4. The compound of claim 2 wherein R₁ is hydrogen and R₃ and R₄ are substituted on adjacent carbon atoms and taken together with their attached carbon atoms form a fused aromatic ring and R₂ is selected from hydrogen and lower alkyl.
 5. The compound of claim 4 wherein said compound is 7-methyl-6-naphthalen-1-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 6. The compound of claim 4 wherein said compound is 7-methyl-6-naphthalen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 7. The compound of claim 4 wherein said compound is 6-naphthalen-1-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 8. The compound of claim 4 wherein said compound is 6-naphthalen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 9. The compound of claim 8 wherein said compound is 7-methyl-6-naphthalen-1-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 10. The compound of claim 1 wherein R₃ and R₄ are substituted on adjacent carbon atoms on the phenyl ring and taken together form a fused heteroaromatic ring; and R₁ and R₂ are independently selected from hydrogen and lower alkyl.
 11. The compound of claim 10 wherein said compound is 6-(3,5-6-Benzo[b]thiophen-7-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 12. The compound of claim 1 wherein R₃ and R₄ are attached on adjacent carbon atoms on the phenyl ring and form a two membered ring system, one of said rings being a heteroaromatic ring and the other being an aromatic ring.
 13. The compound of claim 12 wherein said compound is 7-methyl-6-phenoxathiin-4-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 14. The compound of claim 1 wherein R₁ and R₂ are independently selected from hydrogen and lower alkyl, and R₃ and R₄ are independently selected from the group consisting of hydrogen, lower alkyl and lower alkenyl.
 15. The compound of claim 14 wherein R₄ is lower alkenyl and R₃ is hydrogen.
 16. The compound of claim 15 wherein said compound is 7-methyl-6-(4-vinyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 17. The compound of claim 14 wherein R₄ is selected from lower alkyl and hydrogen, and R₃ is lower alkenyl.
 18. The compound of claim 17 wherein said compound 7-methyl-6-o-tolyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 19. The compound of claim 17 wherein said compound 6-(2,5-dimethyl-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 20. The compound of claim 17 wherein said compound is 7-methyl-6-m-tolyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 21. The compound of claim 17 wherein said compound 6-(4-ethyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 22. The compound of claim 17 wherein said compound 6-(4-tert-butyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 23. The compound of claim 1 wherein R₁ and R₂ are independently selected from hydrogen and lower alkyl, R₃ and R₄ are independently selected from hydrogen, halogen, trifluoroloweralkyl; and one of R₃ and R₄ is other than hydrogen.
 24. The compound of claim 23 wherein said compound is 6-(3,5-bis-trifluoromethyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.
 25. The compound of claim 23 wherein said compound is 6-(4-fluoro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 26. The compound of claim 23 wherein said compound is 6-(3-fluoro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 27. The compound of claim 23 wherein said compound is 6-(2,4-dichloro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 28. The compound of claim 23 wherein said compound is 6-(2-chloro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 29. The compound of claim 23 wherein said compound is 6-(2-trifluoromethyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.
 30. The compound of claim 23 wherein said compound is 6-(3-fluoro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 31. The compound of claim 23 wherein said compound is 6-(2,4-dichloro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 32. The compound of claim 23 wherein said compound is 7-methyl-6-(4-trifluoromethoxy-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 33. The compound of claim 23 wherein said compound is 6-(3,4-dichloro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 34. The compound of claim 1 wherein R₁ and R₂ are independently selected from hydrogen and lower alkyl; R₃ is selected from hydrogen and halogen; and R₄ is selected from the group consisting of halogen, nitro, lower alkoxy, phenoxy, hydroxy, hydroxyalkyl,

v is an integer selected from 0 to 4; and R₁₂ is selected from hydrogen and lower alkyl.
 35. The compound of claim 34 wherein R₃ is selected from hydrogen and halogen, and R₄ is selected from the group consisting of nitro, halogen, phenoxy, lower alkoxy, hydroxy and hydroxyalkyl.
 36. The compound of claim 35 wherein said compound is 6-(3-ethoxy-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 37. The compound of claim 35 wherein said compound is 6-(3-nitro-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.
 38. The compound of claim 35 wherein said compound is 6-(5-chloro-2-methoxy-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 39. The compound of claim 35 wherein said compound is [3-(1,3-diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-methanol trifluoro-acetic acid salt.
 40. The compound of claim 35 wherein said compound is 6-(5-fluoro-2-methoxy-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 41. The compound of claim 35 wherein said compound is 6-(2,6-difluoro-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 42. The compound of claim 35 wherein said compound is 7-methyl-6-(2-phenoxy-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 43. The compound of claim 34 wherein R₃ is hydrogen, R₄ is

and R₁₂ is selected from hydrogen and lower alkyl.
 44. The compound of claim 43 wherein said compound is 3-(1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-benzaldehyde.
 45. The compound of claim 43 wherein said compound is 1-[3-(1,3-diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-ethanone trifluoro-acetic acid salt.
 46. The compound of claim 34 wherein R₃ and R₄ are independently selected from hydrogen and

v is as above; R₁ and R₂ are selected from hydrogen and lower alkyl; and one of R₃ and R₄is other than hydrogen.
 47. The compound of claim 46 wherein said compound is 3-[2-(1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-propionic acid.
 48. The compound of claim 46 wherein said compound is [3-(1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-acetic acid.
 49. The compound of claim 46 wherein said compound is [4-(1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-acetic acid.
 50. The compound of claim 46 wherein said compound is 3-[3-(1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-phenyl]-propionic acid.
 51. The compound of claim 1 wherein R₁ and R₂ are independently selected from hydrogen and lower alkyl; R₃ and R₄ are selected from the group consisting of hydrogen, R₅ R₆ N—,

and R₇S—; R₅ and R₆ are independently selected from hydrogen and lower alkyl; R₇ is lower alkyl; and one of R₃ and R₄is other than hydrogen.
 52. The compound of claim 51 wherein said compound is 6-(3-amino-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 53. The compound of claim 51 wherein said compound is 6-(4-ethylsulfanyl-phenyl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 54. The compound of claim 1 wherein R₂ is selected from —(CH₂)_(n)—CH₂—OR₁₃ or

R₁₃ is selected from the group consisting of hydrogen, phenyl, benzyl and lower alkyl; and n is an integer from 0 to
 4. 55. The compound of claim 54 wherein said compound is 2-[1,3-diamino-6-(2-trifluoromethyl-phenyl)-pyrrolo[3,2-f]quinazolin-7-yl]-ethanol trifluoro-acetic acid salt.
 56. The compound of claim 55 wherein said compound is 7-(2-benzyloxy-ethyl)-6-(2-trifluoromethyl-phenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 57. The compound of claim 55 wherein said compound is [1,3-diamino-6-(2-trifluoromethyl-phenyl)-pyrrolo[3,2-f]quinazolin-7-yl]-acetic acid trifluoro-acetic acid salt.
 58. The compound of claim 1 wherein R₂ is

R₁₀ and R₁₁, are independently selected from hydrogen and lower alkyl.
 59. The compound of claim 58 wherein said compound is 2-[1,3-diamino-6-(3-methoxy-phenyl)-pyrrolo[3,2-f]quinazolin-7-yl]—N,N-diethyl-acetamide.
 60. A compound of the formula:

wherein {circle over (P)} is a 5 or 6 membered heteroaromatic ring containing from 1 to 2 hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen; R1 is selected from hydrogen and lower alkyl; R₂ is selected from the group consisting of hydrogen,

R₃ and R₄ are independently selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkoxy, hydroxy lower alkyl, perfluoroloweralklyl, nitro, halo, lower alkanoyl, —N R₅R₆, R₇S—,

phenyl, hydroxy, perfluoroloweralkoxy, and phenoxy, or R₃ and R₄ when present on adjacent carbon atoms on the heteroaromatic ring can be taken together to form a lower alkylene bridge or taken together with their adjacent carbon atoms to form an aromatic ring system fused to the heteroaromatic ring, said aromatic ring system containing one or two aromatic rings with one of said rings being either an aromatic or heteroaromatic ring; R₅ and R₆ are selected from hydrogen and lower alkyl; R₂ is selected from the group consisting of hydrogen, benzyl, phenyl and lower alkyl; R₇ is lower alkyl; R₁₃ is selected from the group consisting of hydrogen, lower alkyl, benzyl and phenyl; R₁₀, R₁₁ and R₁₂ are independently selected from hydrogen and lower alkyl; and m, n, o and v are independent integers selected from 0 to 4, or pharmaceutically acceptable salts thereof,
 61. The compound of claim 60 wherein {circle over (P)} is a heteroaromatic ring containing sulfur as the only hetero atom.
 62. The compound of claim 61 wherein R₃ and R₄ are independently selected from hydrogen, halogen and lower alkyl.
 63. The compound of claim 62 wherein said compound is 7-methanesulfonyl-6-thiophen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 64. The compound of claim 62 wherein said compound is 7-methyl-6-thiophen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.
 65. The compound of claim 62 wherein said compound is 6-(5-chloro-thiophen-2-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 66. The compound of claim 61 wherein R₃ and R₄ is selected from hydrogen and

R₁₂ is selected from hydrogen and lower alkyl; and R₃ and R₄ are other than hydrogen.
 67. The compound of claim 66 wherein said compound is 1-[5-(1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-6-yl)-thiophen-2-yl]-ethanone trifluoro-acetic acid salt.
 68. The compound of claim 66 wherein said compound is 1-[5-(1,3-diamino-7-methyl-7H-pyrrolo[3,2-f]quinazolin-6-yl)-thiophen-2-yl]-ethanone trifluoro-acetic acid salt.
 69. The compound of claim 60 wherein R₃ and R₄ are attached to the hetero atom ring on adjacent carbon atoms and taken together with their attached carbon atoms a fused phenyl ring.
 70. The compound of claim 69 wherein said compound is 6-benzo[b]thiophen-2-yl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 71. The compound of claim 69 wherein said compound is 6-benzo[b]thiophen-2-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 72. The compound of claim 66 wherein said compound is 6-benzofuran-2-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.
 73. The compound of claim 60 wherein {circle over (P)} is a heteroaromatic ring containing an oxygen atom as the only hetero atom.
 74. The compound of claim 73 wherein said compound is 6-furan-2-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 75. The compound of claim 73 wherein said compound is 6-benzofuran-2-yl-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine
 76. The compound of claim 60 wherein {circle over (P)} is a heteroaromatic ring containing a nitrogen hetero atom.
 77. The compound of claim 76 wherein said compound is 6-(3,5-dimethyl-isoxazol-4-yl)-7-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine trifluoro-acetic acid salt.
 78. A pharmaceutical composition comprising one or more of the compounds of the formula:

wherein R₁ is selected from hydrogen and lower alkyl; R₂ is selected from the group consisting of hydrogen, lower alkyl,

R₃ and R₄ are independently selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkoxy, hydroxy lower alkyl, perfluoroloweralklyl, nitro, halo, lower alkanoyl, —N R₅R₆, R₇S—,

phenyl, hydroxy, perfluoroloweralkoxy, and phenoxy, or R₃ and R₄ when present on adjacent carbon atoms on the phenyl ring can be taken together with their adjacent carbon atoms to form a lower alkylenedioxy bridge or an aromatic ring system fused to the phenyl ring, said aromatic ring system containing one or two aromatic rings with one of said rings being either an aromatic or heteroaromatic ring; R₅ and R₆ are selected from hydrogen and lower alkyl; R₁₂ is selected from the group consisting of hydrogen, benzyl, phenyl and lower alkyl; R₇ is lower alkyl; R₁₃ is selected from the group consisting of hydrogen, lower alkyl, benzyl and phenyl; R₁₀, R₁₁ and R₁₂ are independently selected from hydrogen and lower alkyl; and m, n, o and v are independent integers selected from 0 to 4; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
 79. A pharmaceutical composition comprising one or more of the formula:

wherein {circle over (P)} is a 5 or 6 membered heteroaromatic; ring containing from 1 to 2 hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen; R₁ is selected from hydrogen and lower alkyl; R₂ is selected from the group consisting of hydrogen,

R₃ and R₄ are independently selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkoxy, hydroxy lower alkyl, perfluoroloweralklyl, nitro, halo, lower alkanoyl, —N R₅R, R₇S—,

phenyl, hydroxy, perfluoroloweralkoxy, and phenoxy, or R₃ and R₄ when present on adjacent carbon atoms on the heteroaromatic ring can be taken together with their adjacent carbon atoms to form a lower alkylenedioxy bridge or an aromatic ring system fused to the phenyl ring, said aromatic ring system containing one or two aromatic rings with one of said rings being either an aromatic or heteroaromatic ring; R₅ and R₆ are selected from hydrogen and lower alkyl; R₂ is selected from the group consisting of hydrogen, benzyl, phenyl and lower alkyl; R₇ is lower alkyl; R₁₃ is selected from the group consisting of hydrogen, lower alkyl, benzyl and phenyl; R₁₀, R₁₁ and R₁₂ are independently selected from hydrogen and lower alkyl; and m, n, o and v are independent integers selected from 0 to 4 or pharmaceutically acceptable salts thereof.
 80. A method of treating a disease based on high blood glucose concentration comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one compound of the formula:

wherein, R₁ is selected from hydrogen and lower alkyl; R₂ is selected from the group consisting of hydrogen, lower ally,

R₃ and R₄ are independently selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkoxy, hydroxy lower alkyl, perfluoroloweralklyl, nitro, halo, lower alkanoyl, —N R₅R₆, R₇S—,

phenyl, hydroxy, perfluoroloweralkoxy, and phenoxy, or R₃ and R₄ when present on adjacent carbon atoms on the phenyl ring can be taken together with their adjacent carbon atoms to form a lower alkylenedioxy bridge or an aromatic ring system fused to the phenyl ring, said aromatic ring system containing one or two aromatic rings with one of said rings being either an aromatic or heteroaromatic ring; R₅ and R₆ are selected from hydrogen and lower alkyl; R₁₂ is selected from the group consisting of hydrogen, benzyl, phenyl and lower alkyl; R₇ is lower alkyl; R₁₃ is selected from the group consisting of hydrogen, lower alkyl, benzyl and phenyl; R₁₀, R₁₁ and R₁₂ are independently selected from hydrogen and lower alkyl; and m, n, o and v are independent integers selected from 0 to 4 or pharmaceutically acceptable salts thereof.
 81. A method of treating a disease based on high blood glucose concentration comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one compound of the formula:

wherein, {circle over (P)} is a 5 or 6 membered heteroaromatic ring containing from 1 to 2 hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen; R1 is selected from hydrogen and lower alkyl; R₂ is selected from the group consisting of hydrogen,

R₃ and R₄ are independently selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkoxy, hydroxy lower alkyl, perfluoroloweralklyl, nitro, halo, lower alkanoyl, —N R₅R₆, R₇S—,

phenyl, hydroxy, perfluoroloweralkoxy, and phenoxy, or R₃ and R₄ when present on adjacent carbon atoms on the heteroaromatic ring can be taken together with their adjacent carbon atoms to form a lower alkylenedioxy bridge or an aromatic ring system fused to the phenyl ring, said aromatic ring system containing one or two aromatic rings with one of said rings being either an aromatic or heteroaromatic ring; R₅ and R₆ are selected from hydrogen and lower alkyl; R₂is selected from the group consisting of hydrogen, benzyl, phenyl and lower alkyl; R₇ is lower alkyl; R₁₃ is selected from the group consisting of hydrogen, lower alkyl, benzyl and phenyl; R₁₀, R₁₁ and R₁₂ are independently selected from hydrogen and lower alkyl; and m, n, o and v are independent integers selected from 0 to 4 or pharmaceutically acceptable salts thereof. 